Technology
Health
Pharmaceutical

Galmed Pharmaceuticals

$5.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.47 (9.22%) Today
-$0.03 (-0.54%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell GLMD and other stocks, options, ETFs, and crypto commission-free!

About GLMD

Galmed Pharmaceuticals Ltd. Ordinary Shares, also called Galmed Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Employees
21
Headquarters
Tel Aviv, Tel Aviv
Founded
2000
Market Cap
117.64M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
99.14K
High Today
$5.59
Low Today
$5.09
Open Price
$5.11
Volume
40.08K
52 Week High
$14.65
52 Week Low
$4.50

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2014 IPO
Asia (Non-China)

GLMD News

ReutersAug 12

Edited Transcript of GLMD earnings conference call or presentation 5-Aug-19 12:30pm GMT

3

GLMD Earnings

-$0.27
-$0.20
-$0.12
-$0.05
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.22 per share
Actual
-$0.20 per share

More GLMD News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.